Latest Close
$5.20
Stock Hub
ABCL
AbCellera Biologics Inc.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Use the sections below to move between chart, technical analysis, fundamentals, and news.
1y Change
$3.23 (+163.96%)
Market Cap
$1.59B
Sector
Healthcare
Industry
Biotechnology
Recommendation
strong_buy
52W Range
$1.97 to $6.52
Target Mean Price
$10.43
Beta
Not available
Trailing P/E
Not available
Forward P/E
-7.22
Price / Book
1.69
Company Overview
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.